[ad_1]
Photo source, Reuters
Remdesivir
Regulatory authorities in the US have officially approved the use of remdesivir, an antiviral drug, to treat a new coronavirus infection (Corona 19).
As a result of clinical trials, the recovery period of patients who administered the remdesivir brand name ‘Veklery’ was found to be 5 days faster on average.
The US Food and Drug Administration (FDA) said in a statement that “Becklery is the first Corona 19 treatment approved by the FDA.”
However, the World Health Organization (WHO) said last week that remdesivir had little effect on the survival of patients with corona19.
The WHO explained that it was based on its own research, but Gilead, the maker of remdesivir, considered the results of the experiment inappropriate.
Remdesivir has been approved for emergency use in the United States since last May.
President Donald Trump, who was diagnosed with Corona 19, was also treated with remdesivir and has since recovered.
What did the FDA say?
In a statement, the FDA explained that remdesivir can only be used in patients 12 years of age or older and weighing more than 40 kg among patients requiring hospitalization for Corona 19.
FDA Director Stephen Han said: “This approval was based on data from several clinical trials that were rigorously evaluated by the FDA and is a major scientific milestone in the COVID-19 pandemic.”
The FDA said, “We analyzed data from three randomized controlled clinical trials of hospitalized patients for COVID-19, ranging from mild to severe, and made decisions based on that.”
Additionally, the FDA reported that the study found that the group that took Becklery had a recovery period of 10 days, and that the group that did not take it was 15 days.
Photo source, fake images
Manufacturer of Remdesivir Gilead
How was the WHO study?
Previously, the WHO measured the effects of four drugs for joint clinical trials.
The drugs used in the trial were remdesivir, hydroxychloroquine, an antimalarial treatment, interferon, an autoimmune, and lopinavir and ritonavir, a combination treatment for the human immunodeficiency virus (HIV).
It does not include dexamethasone, a low-cost steroid currently widely used in severe COVID-19 patients in the UK.
This experiment involved a total of 11,266 adult patients in 500 hospitals in more than 30 countries around the world.
The WHO said the findings were not peer-reviewed, but that the four drugs, including remdesivir, did not have a substantial effect on patient mortality or length of stay.
